1. Clinical & Scientific Overview
Risperidone IP & Olanzapine IP (TIP-MED-000413, Reference Code [11.24]-CMP143) is classified under
CNS & Psychiatric Medicines (Ch 11) as a Third-Generation Quinolinone Antipsychotic (Dopamine D2 / Serotonin 5-HT1A Partial Agonist).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed per approved Author Decision DEC-02 (Option 2A; displaced HTML [11.24] & Inventory CSV mono-11-28). Compared with Risperidone and Olanzapine, Aripiprazole (D2 partial agonist) lowers prolactin and has minimal metabolic weight gain.
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decision DEC-02 (Option 2A; displaced HTML [11.24] & Inventory CSV mono-11-28). Compared with Risperidone and Olanzapine, Aripiprazole (D2 partial agonist) lowers prolactin and has minimal metabolic weight gain.
4. Therapeutic Indications & Evidence-Supported Uses
- Schizophrenia
- bipolar I mania and maintenance
- adjunct in major depressive disorder
- irritability associated with autism
- Tourette syndrome
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-02 (Option 2A; displaced HTML [11.24] & Inventory CSV mono-11-28). Compared with Risperidone and Olanzapine, Aripiprazole (D2 partial agonist) lowers prolactin and has minimal metabolic weight gain.
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [11.24].
Renal: No dose adjustment required in renal impairment. • Hepatic: Mild-to-moderate impairment: No adjustment. Severe cirrhosis: Titrate cautiously from lower starting dose.
Renal: No dose adjustment required in renal impairment. • Hepatic: Mild-to-moderate impairment: No adjustment. Severe cirrhosis: Titrate cautiously from lower starting dose.
Renal: No dose adjustment required in renal impairment. • Hepatic: Mild-to-moderate impairment: No adjustment. Severe cirrhosis: Titrate cautiously from lower starting dose.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Known hypersensitivity to aripiprazole. • Precautions: High incidence of early akathisia (inner restlessness) and insomnia; FDA/CDSCO warning for rare impulse-control disorders (pathological gambling, compulsive shopping/binge eating); minimal prolactin or metabolic elevation.
Key Clinical Precautions: Renal: No dose adjustment required in renal impairment. • Hepatic: Mild-to-moderate impairment: No adjustment. Severe cirrhosis: Titrate cautiously from lower starting dose.
8. Adverse Effects Profile
- Akathisia, restlessness, insomnia, nausea, headache, tremor.
- Pathological impulse-control behaviours, tardive dyskinesia, neuroleptic malignant syndrome.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- CYP2D6 inhibitors (Fluoxetine, Paroxetine) or CYP3A4 inhibitors (Ketoconazole, Clarithromycin) -> reduce Aripiprazole dose by 50%; Carbamazepine -> double Aripiprazole dose
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.24].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Take in the morning if it causes insomnia; report severe inner restlessness (pacing/inability to sit still) or unusual urges (gambling/spending).
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Non-NLEM | Compendia: IP 2026 / NFI 7th Ed 2026 / CDSCO Schedule H / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablet / Mouth-Dissolving Tablet (MT): 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.6] Lorazepam (Oral Tablets & Parenteral IV/IM Status Epilepticus) — Intermediate-Acting 3-Hydroxy Benzodiazepine (Direct Phase-II Glu
- [11.7] Amitriptyline Hydrochloride — Tertiary-Amine Tricyclic Antidepressant (TCA; Serotonin & Norepin
- [11.17] Zolpidem Tartrate (Non-BZD Z-Drug Hypnotic) — Non-Benzodiazepine Imidazopyridine Hypnotic ('Z-Drug'; Selective
- [11.18] Venlafaxine Hydrochloride & Desvenlafaxine Succinate — Serotonin–Noradrenaline Reuptake Inhibitors (SNRIs)
/medicine/11-24-risperidone-olanzapine/ for complementary therapeutic comparison and dosing context.